Conclusion
It is a pivotal time in overcoming the current outbreak of the
2019-nCoV. The decoction of the specified drugs listed should be
assessed for their efficacy and safety and stability, and should also be
evaluated for the treatment and recovery of patients suffering from the
2019-nCoV in carefully planned clinical trials, either used alone or
integrated with other drugs. Many of the potential drugs under different
phases of clinical trials (eg: Remdesivir, Lopinavir, Ritonavir,
Darunavir, Cobicistat etc. are in phase III, Oseltamivir is in phase
IVof clinical trials, and many others are in preclinical stage of
trials) can be successful in battling COVID-19
[10][37][43][47]. The vital ethical concern in the
COVID-19 setting for the administration of repurposable drugs are
experimental and, thus, require ethical or off-label approval of trials
[55].We will keep cautiously optimistic before releasing successful
clinical trial results as the lessons from a recent public panic buying
spree, which revealed results of a preliminary study and induced
irrational purchases overnight, should also be taken into account. In
this study, our approach will reduce the translational gap between
preclinical research results and clinical outcomes, which is a major
problem in the rapid production of successful drugs, discovered for the
emerging 2019-nCoV / SARS-CoV-2 outbreak.